[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 124, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 67, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 1366917, "exercisedValue": 41362, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Asif  Ali", "age": 50, "title": "Executive VP & CFO", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 805042, "exercisedValue": 586039, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suneel K. Gupta Ph.D.", "age": 66, "title": "Executive Vice President of Clinical Development", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 896847, "exercisedValue": 7759965, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arturo M. Molina FACP, M.D., M.S.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 956912, "exercisedValue": 1160875, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohammad  Masjedizadeh Ph.D.", "title": "Executive VP & CTO", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Newman  Yeilding", "title": "Executive VP, Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew M. Gosling J.D.", "age": 53, "title": "Executive VP & General Counsel", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carena  Spivey", "title": "Head of HR & Senior VP of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashok  Bhandari Ph.D.", "age": 60, "title": "EVP & Chief Discovery Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carter J. King", "age": 53, "title": "Executive Vice President of Business Development", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1751328000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 53.74, "open": 53.85, "dayLow": 53.06, "dayHigh": 55.245, "regularMarketPreviousClose": 53.74, "regularMarketOpen": 53.85, "regularMarketDayLow": 53.06, "regularMarketDayHigh": 55.245, "payoutRatio": 0.0, "beta": 2.255, "trailingPE": 70.70513, "forwardPE": -38.566437, "volume": 477255, "regularMarketVolume": 477255, "averageVolume": 864079, "averageVolume10days": 683330, "averageDailyVolume10Day": 683330, "bid": 55.04, "ask": 55.32, "bidSize": 1, "askSize": 1, "marketCap": 3418307328, "fiftyTwoWeekLow": 32.5, "fiftyTwoWeekHigh": 60.6, "priceToSalesTrailing12Months": 16.44991, "fiftyDayAverage": 51.9462, "twoHundredDayAverage": 45.3202, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2855304704, "profitMargins": 0.27041999, "floatShares": 42985106, "sharesOutstanding": 61982000, "sharesShort": 6183934, "sharesShortPriorMonth": 5913322, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.0998, "heldPercentInsiders": 0.01052, "heldPercentInstitutions": 1.08462, "shortRatio": 6.65, "shortPercentOfFloat": 0.1197, "impliedSharesOutstanding": 61982000, "bookValue": 11.127, "priceToBook": 4.9564123, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": 56193000, "trailingEps": 0.78, "forwardEps": -1.43, "enterpriseToRevenue": 13.741, "enterpriseToEbitda": 101.783, "52WeekChange": 0.4210255, "SandP52WeekChange": 0.16932249, "quoteType": "EQUITY", "currentPrice": 55.15, "targetHighPrice": 82.0, "targetLowPrice": 41.0, "targetMeanPrice": 69.0, "targetMedianPrice": 70.0, "recommendationMean": 1.45455, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 574360000, "totalCashPerShare": 9.267, "ebitda": 28053000, "totalDebt": 11360000, "quickRatio": 17.129, "currentRatio": 17.255, "totalRevenue": 207800992, "debtToEquity": 1.649, "revenuePerShare": 3.347, "returnOnAssets": 0.02481, "returnOnEquity": 0.089949995, "grossProfits": 207800992, "freeCashflow": 327758016, "operatingCashflow": 336944000, "revenueGrowth": -0.889, "grossMargins": 1.0, "ebitdaMargins": 0.135, "operatingMargins": -0.68183, "financialCurrency": "USD", "symbol": "PTGX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Protagonist Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1753474319, "regularMarketTime": 1753473600, "exchange": "NGM", "messageBoardId": "finmb_129263324", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.62374, "regularMarketPrice": 55.15, "marketState": "CLOSED", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 864079, "fiftyTwoWeekLowChange": 22.650002, "fiftyTwoWeekLowChangePercent": 0.69692314, "fiftyTwoWeekRange": "32.5 - 60.6", "fiftyTwoWeekHighChange": -5.449997, "fiftyTwoWeekHighChangePercent": -0.08993395, "fiftyTwoWeekChangePercent": 42.10255, "earningsTimestamp": 1746561600, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1754942400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.78, "epsForward": -1.43, "epsCurrentYear": -1.6527, "priceEpsCurrentYear": -33.36964, "fiftyDayAverageChange": 3.2038002, "fiftyDayAverageChangePercent": 0.06167535, "twoHundredDayAverageChange": 9.8298, "twoHundredDayAverageChangePercent": 0.21689664, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "shortName": "Protagonist Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470922200000, "postMarketChangePercent": 0.0, "postMarketPrice": 55.15, "postMarketChange": 0.0, "regularMarketChange": 1.41, "regularMarketDayRange": "53.06 - 55.245", "displayName": "Protagonist Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-26"}]